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ABSTRACT 
Background: B-type natriuretic peptide (BNP) is known to be a risk marker following acute 
myocardial infarction (MI). More recently, truncated molecular forms of the BNP molecule 
have been identified, with the association of these forms and outcome in acute MI not known. 
The present study investigated their use as risk stratifying biomarkers of this condition. 
Methods: BNP molecular forms (BNP 5-32, BNP 4-32 and BNP 3-32) were measured in 
plasma from 1,078 acute MI patients using immunocapture followed by MALDI-ToF-mass 
spectrometry. Associations of molecular forms with short-term and long-term adverse 
outcomes were assessed.  
Results: BNP molecular forms were independent predictors of mortality/reinfarction, 
mortality/rehospitalization due to heart failure, and a composite of all events at 6 months, 1 
year and 2 years and showed prognostic ability comparable with conventional BNP 
measurements (P <0.001-0.026 vs. N-terminal [NT]-proBNP P <0.001-0.020, respectively). 
Reclassification analyses showed BNP molecular forms successfully reclassified patient risk 
when used in addition to the GRACE clinical risk score (P ≤0.005). BNP 5-32 showed utility 
as a secondary risk stratification biomarker when used in combination with the GRACE score 
and NT-proBNP by successful down-classification of high-risk patients. 
Conclusions: BNP molecular forms were associated with poor prognosis at 6 months, 1 year 
and at 2 years in patients with acute MI. BNP 5-32 showed successful utility as a secondary 
marker in combination with NT-proBNP after GRACE scoring. This study suggests a 
potential role for BNP molecular forms in prognosis and risk stratification after acute MI. 
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INTRODUCTION 
 B-type natriuretic peptide (BNP), and its N-terminal pro hormone (NT-proBNP), have 
been shown to be biomarkers of risk stratification and outcomes of patients following acute 
myocardial infarction (MI).  Previous investigations have shown elevated levels of BNP or 
NT-proBNP are associated with in-hospital (1) and short-term (30-day) mortality (2), as well 
as mortality at extended follow-up periods of 4 years or more (3-5). From a 
pathophysiological standpoint, measured circulating levels of the BNP family of peptides 
have also shown associations with infarct size (6), degree of systolic dysfunction (7), 
development of heart failure (8) and cardiac death (9). Therefore, BNP peptides have been 
able to provide complementary clinical information beyond traditional MI biomarkers such as 
troponin and copeptin (3). 
Truncated BNP fragments, or BNP molecular forms, are produced from proteolytic 
degradation of parent BNP molecules causing removal of end-chain amino acids groups, 
resulting in a range of fragmented peptides (e.g. BNP 3-29, 3-30, 4-29, 5-29 etc.) (10, 11). 
The most common molecular forms have been identified as BNP 5-32, BNP 4-32 and BNP 3-
32 which possess the structure of BNP 1-32 with the removal of 4, 3 and 2 amino acids, 
respectively (10). The mechanistic pathways leading to the production of BNP molecular 
forms are not fully understood. Previous reports have suggested the involvement of multiple 
proteases including dipeptidyl peptidase-IV (BNP 3-32) (12), a neutral endopeptidase (BNP 
5-32) processing of BNP 1-32 (13), and a corin-mediated cleavage of proBNP (BNP 4-32) 
(14). BNP molecular forms are understood to be reflective of conventional clinical 
measurements of circulating BNP, showing a greater association with results obtained from 
clinical pathology laboratories than the parent BNP 1-32 molecule measured in isolation (15). 
The biological impact of the degradation of the parent BNP 1-32 molecule currently lacks 
sufficient understanding. Previously, BNP molecular forms were reported to show no 
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differences in their ability to generate cGMP when compared to BNP 1-32 (10). However, in 
vivo actions of BNP molecular form are suggested to exhibit reduced levels of natriuretic 
activity (10). 
BNP molecular forms have been implicated in ischemic heart disease (16) and chronic 
HF (15), and more recently demonstrated as prognostic indicators for acute HF (17). For risk 
prediction following MI, troponin measurements are a robust and conventional way to stratify 
patients (18), with BNP peptides showing similarly successful application as prognostic 
biomarkers (3, 5, 19). Furthermore, BNP has been suggested as a biomarker that reflects the 
severity of ischemia regardless of the extent of irreversibly injury, and therefore provides 
additive and important information in acute MI risk prediction (20). 
The aims of the present study were to characterize circulating BNP molecular forms 
in acute MI patients and to investigate their prognostic ability to assist in risk stratification. 
Comparisons for the use of BNP molecular forms as prognostic indicators in acute MI were 
made with established measurements of circulating BNP (NT-proBNP and clinical BNP) and 
tested in combination with the established GRACE (Global Registry of Acute Coronary 
Events) risk prediction tool for MI (21).  
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MATERIALS AND METHODS 
 
Study population 
One thousand and seventy-eight patients were admitted with acute MI to University 
Hospitals of Leicester, UK, between August 2004 and April 2007. Each patient consented 
(informed and written) to have blood samples taken and outcomes surveyed. This study was 
approved by the local ethics committee and adhered to the Declaration of Helsinki.  
Diagnosis of acute MI was made on the basis that all patients had a cardiac troponin I 
(cTnI) concentration above the 99th percentile, with at least one of the following: chest pain 
lasting >20 min or diagnostic serial electrocardiographic changes consisting of new 
pathological Q-waves or ST-segment and T-wave changes (22), excluding patients with 
malignancy, renal replacement therapy, or previous surgery within 1 month. Estimated 
glomerular filtration rate (eGFR) was calculated from the simplified Modification of Diet in 
Renal Disease formula (23). All patients received standard medical treatment and 
revascularization at the discretion of the attending physician. 
 
Venipuncture 
Peripheral intravenous blood samples were collected at time of discharge in pre-
chilled tubes containing EDTA and aprotinin, and centrifuged at 1500g for 20 min at 4°C. 
Plasma was aliquoted and stored at -80°C until analysis. For analysis, samples were thawed 
at 37°C, prepared, and analyzed immediately.   
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Measurement of BNP molecular forms 
Molecular forms of BNP were measured using a previously described immunocapture 
assay protocol with an analytical range of 20-3000 pg/mL (16, 17). Briefly, molecular forms 
of BNP were isolated and captured from 100 µL plasma using a monoclonal antibody raised 
against the ring region of BNP (Sekisui Medical Co., Tokyo, Japan) bound to magnetic beads 
(Fisher Scientific, Loughborough, UK). Captured forms were then eluted in 3 µL of 0.1% 
trifluoroacetic acid (Sigma-Aldrich, Gillingham, UK), and 0.75 µL spotted onto a metal 
target plate followed by 5 fmol/µL adrenocorticotropic hormone (ACTH) signal peptide 
(Sigma-Aldrich) and 10 mg/mL matrix (2,5-Dihydroxybenzoic acid and α-Cyano-4-
hydroxycinnamic acid, LaserBio Labs, Sophia Antipolis, France) in a 1:1:1 ratio. Samples 
were detected using matrix assisted laser desorption ionization-time of flight-mass 
spectrometry (MALDI-ToF-MS) using an AXIMA Confidence (Shimadzu Corporation, 
Kyoto, Japan) in positive ion mode. A quality control (QC) sample consisting of all three 
BNP fragments at a concentration of 100 fmol/mL was performed daily to ensure analytical 
reproducibility. All peptides were sourced from Peptide Institute Inc., Osaka, Japan. The 
relative standard deviations of these QC analyses (n=44) across the course of the study were 
6.2%, 9.7% and 13.7% for BNP 5-32, BNP 4-32 and BNP 3-32, respectively. An example 
mass spectrum of the quality control sample showing peaks for BNP molecular forms can be 
found in the Supplementary File (Figure S1). Identifications of molecular BNP forms were 
confirmed by comparison of mass-to-charge ratio of detected ions to those detected in the 
positive control. For statistical analyses, mass spectral peak intensities of the BNP molecular 
forms were expressed as a ratio to the internal standard (ACTH). Samples where BNP 
molecular forms were not detectable had their result recorded as equal to the average value of 
the baseline noise:ACTH ratio (a value of 0.03). A visual indication of the baseline noise 
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intensity in comparison to ACTH and BNP 5-32 at a value of 0.210 can be seen in the 
Supplemental File (Figure S2). 
The antibodies used in this study allowed selective immunocapture of BNP molecular 
forms 5-32, 4-32 and 3-32. BNP 1-32, proBNP and other alternative BNP molecular forms 
were not detected for these samples using our experimental protocol. An example mass 
spectrum from a patient sample showing the presence of BNP molecular forms and absence 
of BNP 1-32 and proBNP can be found in the Supplemental File (Figure S3). NT-proBNP 
was measured using a sandwich immunoassay as described previously (5). A subset of 
patients with positive detection of BNP 5-32 (n=617) were analyzed for clinical BNP levels 
using a point-of-care device (RapidPIA®, Sekisui Medical Co.).  
 
End points 
Primary outcomes were composites of all-cause mortality or reinfarction (death/MI), 
all-cause mortality or rehospitalization due to HF (death/HF), as well as death/MI and 
death/HF combined (MACE). Outcomes were measured in all patients for short-term (6 
months) and long-term (1 year and 2 years) risk prediction.  
Addition of BNP molecular forms to the GRACE score for outcomes at 6 months was 
tested for the end point of death/MI. End points were obtained by reviewing the local hospital 
databases and the Office of National Statistics Registry, and by telephone calls to patients, 
and those data were verified by reviewing medical records. One hundred percent follow-up 
was achieved. 
 
 
 8 
 
Statistical analyses 
Statistical analyses were performed using IBM SPSS Statistics (V24, IBM Corp., 
Armonk, New York, USA). Spearman’s rank-order correlations were calculated for 
molecular forms of BNP against NT-proBNP, clinical BNP and other traditional risk markers 
of acute MI and cardiovascular disease. Outcome prediction accuracies were assessed by 
calculating the area under the curve (AUC) of the Receiver Operator Characteristic (ROC) 
for BNP peptides across all end points. Cox proportional hazard analyses were performed to 
identify independent predictors of death/MI, death/HF and MACE at 6 months, 1 year and 2 
years. Values for molecular forms of BNP, NT-proBNP and clinical BNP were log 
transformed. Continuous reclassification analyses (24) were used to assess the utility of 
adding BNP molecular forms and NT-proBNP to the GRACE score for risk assessment at 6 
months. Decision tree analysis was performed using the χ2 automatic interaction detection 
(CHAID). A P-value <0.05 was deemed statistically significant. 
 
Sources of funding 
This work was supported by the Practical Research Project for Life-Style related 
Diseases including Cardiovascular Diseases and Diabetes Mellitus from Japan Agency for 
Medical Research and Development (AMED) (17ek0210011h0005), the Japan Heart 
Foundation, the University of Tokyo, the John and Lucille van Geest Foundation and the 
National Institute for Health Research Leicester Biomedical Research Centre. The authors are 
solely responsible for the design and conduct of this study, all study analyses, the drafting 
and editing of the paper and its final contents. 
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RESULTS 
 
Patient characteristics 
Plasma samples from 1,078 patients admitted to hospital with acute MI were analyzed 
for the presence of BNP molecular forms. Mass spectral peaks for BNP molecular forms 
were detected in a total of 617 (57.2%) samples. A breakdown of the measured end points 
and clinical demographics for the patient cohort is shown in Table I. 
 
Analyses with associated clinical measurements and outcomes 
Spearman’s rank-order correlation analyses showed clinical variables that were 
associated with one or more of the BNP molecular forms to be blood urea, eGFR, age, cTnI 
at admission, heart rate, blood glucose, blood sodium and systolic blood pressure (Table II).  
BNP molecular forms were strongly correlated to each other (rs = 0.798-0.935, P <0.001) and 
NT-proBNP levels (rs = 0.591-0.640, P <0.001). BNP molecular forms were correlated with 
markers of renal dysfunction including blood urea (rs = 0.267-0.272, P <0.001) and eGFR (rs 
= -0.323- -0.343, P <0.001) but at a level that was modestly reduced when compared with 
NT-proBNP; for blood urea (rs = 0.324, P <0.001) and eGFR (rs = -0.376, P <0.001). Patient 
samples with positive detection of BNP 5-32 showed correlation with clinical BNP 
measurements [rs = 0.682, 0.732 and 0.645 (all P <0.001) for BNP 5-32, 4-32 and 3-32, 
respectively] in accordance to previous reports (data not shown) (15). The accuracies for 
prediction of the investigated outcomes were tested by analyzing the AUC (c-statistic) of the 
ROC curve and are shown for all BNP molecular forms and NT-proBNP in Table III. 
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 BNP molecular forms as predictors of death/MI 
To investigate the prognostic ability of BNP molecular forms for death/MI at 6 
months, 1 year and 2 years, Cox survival analyses were conducted using a multivariable 
model adjusted for traditional cardiovascular disease risk factors. The risk factors included in 
the model were age, sex, systolic BP, Killip score >1, STEMI class, revascularization, 
medication at discharge (aspirin, β-blockers, ACE/ARB, statins), renal markers (eGFR and 
urea), admission cTnI levels and past histories of MI/angina, diabetes and hypertension. 
Independent abilities for the molecular forms of BNP and NT-proBNP to predict outcome 
were assessed by adding each marker to the base model. NT-proBNP was a univariate 
predictor of death/MI at 6 months, 1 year and at 2 years (P <0.001), and retained independent 
prediction at these end points (P ≤0.020) when added to the base model (Table IV). Similarly, 
BNP molecular forms were univariate predictors of death/MI at 6 months, 1 year and at 2 
years (all P <0.001). When BNP molecular forms were added to the base model, they 
retained independent prediction at 6 months (BNP 5-32, 4-32, 3-32; P = 0.019, P = 0.017, P 
= 0.026), 1 year (P = 0.004, P = 0.005, P = 0.018) and at 2 years (P = 0.001, P = 0.002, P = 
0.008) showing comparable abilities to NT-proBNP (Table IV). Other independent 
predictors of outcome were age, urea and revascularization.  
 
BNP molecular forms as predictors of death/HF 
To investigate the prognostic ability of BNP molecular forms for death/HF at 6 
months, 1 year and 2 years, Cox survival analyses were conducted using the same 
multivariate base model as described for death/MI. NT-proBNP was a univariate predictor of 
death/HF at 6 months, 1 year and at 2 years (P ≤0.001), and retained independent prediction 
at these end points (P ≤0.001) when added to the base model. BNP molecular forms were 
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also significant univariate predictors of death/HF at 6 months, 1 year and at 2 years (all P 
<0.001). When added to the base model, BNP molecular forms retained independent 
prediction at 6 months (BNP 5-32, 4-32, 3-32; P = 0.026, P = 0.007, P = 0.002), 1 year (P = 
0.007, P = 0.001, P = 0.001) and at 2 years (P = 0.001, P <0.001, P <0.001) showing 
comparable prognostic abilities to NT-proBNP (Table IV). Other independent predictors of 
outcome were age, Killip score >1, STEMI class, systolic BP, β-blockers and statins on 
discharge and eGFR.  
 
BNP molecular forms as predictors of MACE  
NT-proBNP was a univariate predictor of MACE at 6 months, 1 year and at 2 years 
(P <0.001), and retained independent prediction at these end points (P ≤0.005) when added to 
the previously defined base model. BNP molecular forms were also significant univariate 
predictors of MACE at 6 months, 1 year and at 2 years (all P <0.001). When BNP molecular 
forms were added to the model they retained independent prediction at 6 months (BNP 5-32, 
4-32, 3-32; P = 0.017, P = 0.011, P = 0.005), 1 year (P = 0.002, P = 0.001, P = 0.002) and at 
2 years (P <0.001, P <0.001, P <0.001) showing comparable abilities to NT-proBNP (Table 
IV). Other independent predictors of outcome were age, Killip score >1, STEMI class, 
revascularization, systolic BP and β-blockers on discharge. 
 
Comparison of BNP molecular forms against clinical BNP measurements 
 Clinical BNP values were measured using a commercial assay in a subset of samples 
(n=617) with detectable levels of BNP molecular forms. Cox proportional hazards 
regressions were performed using the described clinical base-model to understand the 
predictive ability of BNP molecular forms in comparison with clinical BNP. These analyses 
 12 
 
were performed for all described end points and are shown in Supplemental Table S1. BNP 
and BNP molecular forms showed similar predictive abilities across outcome measures and 
their respective time points. Interestingly, NT-proBNP was not able to predict outcome in this 
subset of patients for time points associated with the end point of Death/MI (P ≥ 0.092). This 
indicated a modest improvement in predictive ability for BNP and its molecular forms over 
NT-proBNP. 
 
Reclassification analyses 
Reclassification analyses were performed using the continuous net reclassification 
improvement index to assess the added value of BNP molecular forms and NT-proBNP to the 
current GRACE clinical risk score for outcome at 6 months. GRACE score values were 
available for a total of 921 (85.4%) patients. Results showed that both NT-proBNP and BNP 
molecular forms showed a total improvement in reclassification when added to the GRACE 
score (P ≤0.005) (Table V). NT-proBNP and BNP 5-32 were able to successfully down-
classify risk in patients without an event and up-classify those with an event, providing a 
successful overall reclassification of patients for adverse event risk (P <0.001). Whilst BNP 
4-32 and BNP 3-32 were able to successfully reclassify overall patient risk (P = 0.005 and P 
= 0.003, respectively), the effect was weakened in both molecular forms through an inability 
to successfully up-classify patients with events (Table V).  
 
Decision tree analysis 
Decision tree analysis was performed to assess the utility of using BNP 5-32 and NT-
proBNP as secondary risk stratification markers after applying the GRACE score for risk 
prediction (death/MI at 6 months). Results showed that using GRACE as the primary 
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classifier, a score >138 and NT-proBNP concentration above 1834.4 pmol/L identified the 
highest risk group (n=143), with a group event risk of 39.2%. In contrast, a GRACE score of 
≤138 and BNP 5-32 value of ≤0.240 identified the lowest risk group (n=444), with a group 
event risk of 6.5% showing successful down-stratification of patient risk. Kaplan-Meier 
survival analysis for the outcome of death/MI at 6 months with patients stratified into three 
groups, as defined by the decision tree analysis, showed a significant increase in risk across 
the groups (P ≤0.001) with a fold-increase in risk of 2.6 and 9.1 for the middle- and high-risk 
groups when compared to the low-risk reference group (P <0.001), respectively (Figure 1). 
These data support the combined use of NT-proBNP and BNP molecular forms as secondary 
risk stratification biomarkers for acute MI patients in combination with established clinical 
risk algorithms. 
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DISCUSSION 
This study reports that molecular forms of BNP are associated with poor outcome in 
patients hospitalized with acute MI, and the utility of these molecular forms in clinical risk 
prediction. The results showed that molecular BNP forms 5-32, 4-32 and 3-32 were all 
independently able to predict death/MI, death/HF and MACE at 6 months, 1 year and at 2 
years after adjustment for traditional clinical and physiological factors. These prognostic 
qualities were comparable to conventional measurements of circulating BNP through analysis 
of plasma NT-proBNP and clinical BNP concentrations. Although clinical measurements of 
BNP have been shown as useful in prediction of outcome after acute MI for long-term 
survival (3), this is the first study to report the prognostic capabilities of BNP molecular 
forms in an acute MI cohort. These findings extend from previous evidence for the utility of 
BNP molecular forms in acute HF prognosis (17).  
Similarly to results previously published in acute HF (17), BNP 5-32 exhibited mildly 
superior risk prediction capabilities when compared to alternative molecular forms. The BNP 
molecular forms were successfully able to predict outcome at all measured endpoints, with an 
improvement in prognostic qualities with extended follow-up periods. This suggests that 
although suitable for shorter-term prediction, BNP molecular forms offer improved 
information for risk stratification over time.  
Reclassification analyses were performed after combining BNP molecular forms with 
the established GRACE risk prediction tool for death/MI at 6 months and showed an added 
benefit for the use of BNP molecular forms. BNP 5-32 was the superior molecular form with 
the ability to reclassify patients for both increased and decreased risk after classification by 
the GRACE score and was comparable to results obtained for NT-proBNP. In contrast, 
although BNP 4-32 and BNP 3-32 were successful in an overall reclassification of patient 
 15 
 
risk, this was centered on their strong ability to down-classify risk with both molecular forms 
reporting negative net reclassification indices for the up-classification of patient risk. 
Reclassification analyses have demonstrated the ability to offer great sensitivity in 
highlighting an improvement for the inclusion of an additional variable to a previously 
calculated value (e.g. clinical risk score) (25). Further improvements in sensitivity are gained 
through the use of continuous category-free reclassification (24), as performed in this 
investigation. However, it has also been argued that reclassification analyses demonstrate an 
oversensitivity for risk stratification (26), and therefore our data should be interpreted in 
combination with the other statistical tests performed. 
BNP 5-32, as the most discriminatory of molecular forms and its improved detection 
in patient samples, was taken forward into decision tree analysis and used in conjunction with 
NT-proBNP to define risk stratification following GRACE scoring. BNP 5-32 identified 
patients at lower risk after initial GRACE screening with NT-proBNP highlighting those at 
highest risk, generating patient groupings that showed a stepped increase in risk. A GRACE 
score of 138 identifies patients in the high-risk category for both non-STEMI and STEMI 
(GRACE score ≥119 for non-STEMI and ≥128 for STEMI) (27). These data suggest the 
beneficial use for combined analyses of BNP family peptides in enhancing risk prediction of 
acute MI patients. In this instance, BNP 5-32 and NT-proBNP were selected as 
complementary secondary biomarkers to a clinical risk algorithm for risk stratification at 6 
months, demonstrating the advantages of BNP molecular forms in addition to current models 
of single BNP peptide analyses. Previous studies have shown NT-proBNP to add prognostic 
value to the GRACE score in elderly patients with acute MI (28) whilst also being able to 
predict early and late mortality in risk stratification after acute coronary syndromes (29). 
Although this study provides information regarding BNP molecular forms in acute 
MI, measurement of these forms does not add tremendously to the significance of natriuretic 
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peptides measured in a conventional way.  The present analyses did not take into account 
proBNP levels as they were not measured using the described mass spectrometric assay 
which might influence the effects of BNP molecular forms in risk prediction. 
In conclusion, the present study shows circulating BNP molecular forms are 
associated with poor prognosis (death/MI, death/HF and MACE) at 6 months, 1 year and at 2 
years. When used in combination with NT-proBNP, BNP 5-32 showed utility as a secondary 
risk stratification biomarker in identifying low-risk patients for outcome at 6 months after 
initial categorization with the GRACE score. This study supports the added value of BNP 
molecular forms to contemporary BNP measurements in prognosis and risk stratification of 
acute cardiovascular hospitalizations. Currently, the assays to measure BNP molecular forms 
are research-focused and further developments of quantitative multiplex assays that allow the 
measurement of multiple BNP forms in a single analysis would be advantageous for clinical 
use. Importantly, care must be taken for future study of these molecular forms for the correct 
collection and storage of samples that is paramount to maintain sample integrity through the 
use of protease inhibitors (e.g. aprotinin) and ultra-cold storage conditions (-80 °C). 
Furthermore, these data show value for further investigations into the dynamics and kinetics 
of BNP degradation as well as BNP pathway responses to disease management strategies.  
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Table I  Patient demographics for acute myocardial infarction admissions. 
Age (yrs) 67 (57-77) 
Male 72% 
Systolic BP (mmHg) 136 (120-151) 
Diastolic BP (mmHg) 77 (68-88) 
Heart rate (beats/min) 75 (63-95) 
Past history MI/angina (%) 33% 
Past history hypertension (%) 52% 
Past history diabetes 23% 
Past history HF 4% 
Aspirin on discharge (%) 84% 
β-blockers on discharge (%) 81% 
ACE/ARB on discharge (%) 84% 
Statins on discharge (%) 89% 
Killip score >1 (%) 41% 
ST elevation MI (%) 47% 
Revascularization (%) 26% 
Glucose (mmol/L) 7.5 (6.3-9.9) 
Troponin (cTnI) (ng/mL) 3.6 (1.0-12.1) 
Urea (mg/dL) 17 (14-22) 
eGFR (mL/min/1.73m2) 66 (53-78) 
Na+ (mmol/L) 138 (136-140) 
K+ (mmol/L) 4.2 (4.0-4.6) 
NT-proBNP (pmol/L) 813 (260-2199) 
GRACE score (22) 120 (96-143) 
BNP 5-32 0.2 (0.03-0.4) 
BNP 4-32 0.04 (0.03-0.2) 
BNP 3-32 0.04 (0.03-0.2) 
  
Endpoints 
 
6 months  
Death/MI 161 
Death/HF 146 
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MACE 209 
  
1 year  
Death/MI 203 
Death/HF 179 
MACE 260 
  
2 years   
Death/MI 232 
Death/HF 200 
MACE 292 
 
Data are reported as median (interquartile range) for continuous variables and as a % for 
categorical data. 
Molecular BNP forms are reported as a ratio of mass spectral peak signal intensity against an 
internal reference standard. 
BNP, B-type natriuretic peptide; BP, blood pressure; eGFR, estimated glomerular filtration 
rate; GRACE, Global Registry of Acute Coronary Events; HF, heart failure; MACE, major 
adverse cardiac event; MI, myocardial infarction,  NT-proBNP, N-terminal pro B-type 
natriuretic peptide; NYHA, New York Heart Association 
 
 
 25 
 
Table II  BNP molecular forms and associated clinical factors. 
 
BNP 5-32 
 
BNP 4-32 
 
BNP 3-32 
 
NT-proBNP 
 
rs P Value 
 
rs P Value 
 
rs P  Value 
 
rs P  Value 
Urea 0.267 <0.001 
 
0.272 <0.001 
 
0.271 <0.001 
 
0.324 <0.001 
eGFR -0.323 <0.001 
 
-0.343 <0.001 
 
-0.329 <0.001 
 
-0.376 <0.001 
Age 0.382 <0.001 
 
0.396 <0.001 
 
0.386 <0.001 
 
0.450 <0.001 
Troponin (cTnI) 0.183 <0.001 
 
0.116 <0.001 
 
0.111 <0.001 
 
0.196 <0.001 
Heart Rate 0.186 <0.001 
 
0.213 <0.001 
 
0.197 <0.001 
 
0.144 <0.001 
Blood Glucose 0.195 <0.001  0.157 <0.001  0.149 <0.001  0.222 <0.001 
Blood Sodium -0.088 0.006  -0.080 0.012  -0.064 0.043  -0.176 <0.001 
Systolic BP -0.074 0.020  -0.055 0.086  -0.057 0.073  -0.094 0.004 
BNP 5-32    0.803 <0.001  0.798 <0.001  0.640 <0.001 
BNP 4-32       0.935 <0.001  0.593 <0.001 
BNP 3-32          0.591 <0.001 
 
BNP, B-type natriuretic peptide; BP, blood pressure; eGFR, estimated glomerular filtration 
rate; NT-proBNP, N-terminal proBNP; rs, Spearman’s rho 
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Table III  Area under the curve (AUC) for the Receiver Operator Characteristic to 
assess the accuracy of outcome prediction of BNP molecular forms and NT-proBNP for 
outcomes of all-cause mortality or reinfarction (death/MI), all-cause mortality or 
rehospitalization due to HF (death/HF) and a composite of all events (MACE) at 6 months, 1 
year and 2 years. Results displayed as AUC (95% CI) P value. 
  Death/MI Death/HF MACE 
BNP 5-32 
   
6 months 0.66 (0.61 - 0.70), P < 0.001 0.71 (0.66 - 0.76), P < 0.001 0.67 (0.63 - 0.71), P < 0.001 
1 year 0.66 (0.62 - 0.70), P < 0.001 0.71 (0.66 - 0.75), P < 0.001 0.67 (0.63 - 0.71), P < 0.001 
2 years 0.66 (0.62 - 0.70), P < 0.001 0.71 (0.67 - 0.75), P < 0.001 0.67 (0.63 - 0.70), P < 0.001 
BNP 4-32 
   
6 months 0.63 (0.58 - 0.68), P < 0.001 0.70 (0.65 - 0.75), P < 0.001 0.65 (0.60 - 0.69), P < 0.001 
1 year 0.64 (0.59 - 0.68), P < 0.001 0.70 (0.66 - 0.75), P < 0.001 0.65 (0.61 - 0.69), P < 0.001 
2 years 0.64 (0.59 - 0.68), P < 0.001 0.70 (0.66 - 0.74), P < 0.001 0.65 (0.61 - 0.69), P < 0.001 
BNP 3-32 
   
6 months 0.63 (0.58 - 0.68), P < 0.001 0.70 (0.65 - 0.75), P < 0.001 0.65 (0.60 - 0.69), P < 0.001 
1 year 0.63 (0.59 - 0.68), P < 0.001 0.70 (0.65 - 0.74), P < 0.001 0.65 (0.60 - 0.69), P < 0.001 
2 years 0.63 (0.59 - 0.68), P < 0.001 0.70 (0.66 - 0.75), P < 0.001 0.65 (0.61 - 0.68), P < 0.001 
NT-proBNP 
   
6 months 0.69 (0.64 - 0.73), P < 0.001 0.78 (0.74 - 0.82), P < 0.001 0.71 (0.67 - 0.75), P < 0.001 
1 year 0.68 (0.64 - 0.72), P < 0.001 0.77 (0.73 - 0.81), P < 0.001 0.70 (0.67 - 0.74), P < 0.001 
2 years 0.68 (0.64 - 0.72), P < 0.001 0.77 (0.73 - 0.80), P < 0.001 0.70 (0.66 - 0.73), P < 0.001 
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Table IV  Independent prediction abilities of BNP molecular forms and NT-proBNP 
using multivariate Cox survival analyses for outcomes of all-cause mortality or reinfarction 
(death/MI), all-cause mortality or rehospitalization due to HF (death/HF) and a composite of 
all events (MACE) at 6 months, 1 year and 2 years. Results displayed as HR (95% CI) P 
value. 
 Death/MI Death/HF MACE 
BNP 5-32    
6 months 1.55 (1.07-2.23), P = 0.019 1.55 (1.05-2.28), P = 0.026 1.46 (1.07-1.99), P = 0.017 
1 year 1.62 (1.17-2.24), P = 0.004 1.60 (1.13-2.27), P = 0.007 1.55 (1.18-2.05), P = 0.002 
2 years 1.70 (1.26-2.30), P = 0.001 1.78 (1.28-2.47), P = 0.001 1.63 (1.25-2.11), P < 0.001 
BNP 4-32    
6 months 1.64 (1.09-2.47), P = 0.017 1.74 (1.16-2.61), P = 0.007 1.55 (1.11-2.18), P = 0.011 
1 year 1.67 (1.17-2.39), P = 0.005 1.86 (1.29-2.67), P = 0.001 1.67 (1.23-2.26), P = 0.001 
2 years 1.71 (1.22-2.39), P = 0.002 1.96 (1.39-2.75), P < 0.001 1.69 (1.27-2.25), P < 0.001 
BNP 3-32    
6 months 1.58 (1.06-2.37), P = 0.026 1.88 (1.25-2.82), P = 0.002 1.63 (1.16-2.29), P = 0.005 
1 year 1.54 (1.08-2.21), P = 0.018 1.88 (1.31-2.72), P = 0.001 1.64 (1.21-2.32), P = 0.002 
2 years 1.58 (1.13-2.21), P = 0.008 2.06 (1.46-2.91), P < 0.001 1.70 (1.28-2.27), P < 0.001 
NT-proBNP    
6 months 1.62 (1.08-2.41), P = 0.019 2.24 (1.40-3.59), P = 0.001 1.72 (1.21-2.45), P = 0.002 
1 year 1.50 (1.07-2.12), P = 0.019 2.02 (1.35-3.02), P = 0.001 1.54 (1.14-2.07), P = 0.005 
2 years 1.44 (1.06-1.96), P = 0.020 2.15 (1.47-3.14), P < 0.001 1.47 (1.12-1.93), P = 0.005 
Models adjusted for: age, sex, PH (past history) MI/angina, Killip score >1, estimated 
glomerular filtration rate, PH diabetes, troponin at admission (cTnI), ST elevation MI, 
revascularization, urea, systolic BP, PH hypertension, aspirin on discharge, β-blockers on 
discharge, ACE/ARB on discharge, statins on discharge  
BNP; B-type natriuretic peptide; HF, heart failure; MACE, major adverse cardiac event; NT-
proBNP, N-terminal proBNP 
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Table V Reclassification analyses for all-cause mortality or reinfarction at 6 months 
using continuous reclassification showing the net reclassification index (NRI) of adding BNP 
molecular forms and NT-proBNP to the classification using the GRACE clinical risk score 
 Endpoint NRI (95% CI) P Value 
BNP 5-32 No 12.2 (5.3-19.1) 0.001 
 Yes 21.2 (4.4-37.9) 0.013 
Total 33.4 (15.3-51.5) <0.001 
BNP 4-32 No 26.9 (20-33.9) <0.001 
Yes -0.7 (-17.5-33.9) NS 
Total 26.2 (8.1-44.3) 0.005 
BNP 3-32 No 31.2 (24.3-38.1) <0.001 
Yes -.36 (-20.4-13.1) NS 
Total 27.5 (9.4-45.6) 0.003 
NT-proBNP No 9.8 (2.8-16.8) 0.006 
Yes 30.9 (14.1-47.7) <0.001 
Total 40.7 (22.5-58.9) <0.001 
 
95% CI, 95% confidence intervals; BNP; B-type natriuretic peptide; NRI, net reclassification 
index; NT-proBNP, N-terminal proBNP 
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Figure 1 Decision tree showing risk stratification for the combined use of the GRACE clinical risk score for all-cause mortality or 
reinfarction (death/MI at 6 months), BNP 5-32 and NT-proBNP and cumulative event incidence of risk groups (inset).  
BNP, B-type natriuretic peptide; NT-proBNP, N-terminal proBNP; OR, odds ratio 
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 Supplemental Figure S1  Example spectra of positive control sample using synthetic 
BNP 5-32, BNP 4-32 and BNP 3-32 (100 fmol/mL) 
 
 
 
 
 
 
 
 
 
ACTH, Adrenocorticotrophic hormone; BNP, B-type natriuretic peptide, m/z, mass-to-charge ratio 
 
 
Supplemental Figure S2  Example spectra showing the ACTH signal, baseline noise 
and BNP 5-32 ratios.  
 
 
 
 
 
  
 
 
 
ACTH, Adrenocorticotrophic hormone; BNP, B-type natriuretic peptide, m/z, mass-to-charge ratio 
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Supplemental Figure S3  Example spectra confirmation of circulating molecular forms 
of BNP detected alongside ACTH signal peptide in acute MI plasma, and non-detection of BNP 1-32 
and proBNP 
 
 
 
 
 
 
 
 
 
 
ACTH, Adrenocorticotrophic hormone; BNP, B-type natriuretic peptide, m/z, mass-to-charge ratio 
 
 
 
 
 
 
 
 Expected mass Actual mass 
A – ACTH 2464.20 2466.84 
B – BNP 5-32 3022.51 3021.92 
C – BNP 4-32 3153.71 3153.31 
D – BNP 3-32 3281.88 3281.24 
E Unknown peak, detected in previously reported studies.  3373.06 
F Unknown peak, detected in previously reported studies.  3444.52 
1-32 3466.08 Undetected 
proBNP 11905.55 Undetected 
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Supplemental Table S1 Independent prediction abilities of traditional cardiac risk markers 
using multivariate Cox survival analyses for outcomes of death/MI, death/HF and MACE at 6 months, 
1 year and 2 years in a subset of samples (n=617) including molecular forms of B-type natriuretic 
peptide (BNP), BNP or N-terminal proBNP (NT-proBNP). 
 
  Death/MI Death/HF MACE 
BNP  
   
6 months 2.07 (1.08-3.98), P = 0.029 2.69 (1.41-5.11), P = 0.003 1.98 (1.14-3.43), P = 0.015 
1 year 2.12 (1.20-3.72), P = 0.009 2.64 (1.49-4.70), P = 0.001 2.12 (1.30-3.47), P = 0.003 
2 years 1.98 (1.17-3.33), P = 0.010 2.77 (1.62-4.74), P < 0.001 2.08 (1.32-3.28), P = 0.002 
BNP 5-32 
   
6 months 2.65 (1.39-5.07), P = 0.003 2.26 (1.22-4.19), P = 0.010 2.03 (1.17-3.50), P = 0.011 
1 year 2.27 (1.30-3.98), P = 0.004 2.26 (1.30-3.92), P = 0.004 1.96 (1.20-3.18), P = 0.007 
2 years 2.22 (1.32-3.74), P = 0.003 2.48 (1.48-4.15), P = 0.001 2.07 (1.32-3.27), P = 0.002 
BNP 4-32 
   
6 months 2.11 (1.24-3.58), P = 0.006 2.01 (1.20-3.34), P = 0.008 1.78 (1.16-2.75), P = 0.009 
1 year 1.92 (1.23-3.01), P = 0.004 2.00 (1.26-3.16), P = 0.003 1.83 (1.25-2.70), P = 0.002 
2 years 1.78 (1.18-2.69), P = 0.006 2.01 (1.31-3.09), P = 0.001 1.76 (1.23-2.52), P = 0.002 
BNP 3-32 
   
6 months 1.86 (1.10-3.15), P = 0.022 2.18 (1.30-3.65), P = 0.003 1.80 (1.16-2.78), P = 0.009 
1 year 1.69 (1.08-2.66), P = 0.022 2.09 (1.31-3.33), P = 0.002 1.75 (1.19-2.59), P = 0.005 
2 years 1.55 (1.02-2.34), P = 0.039 2.20 (1.42-3.40), P < 0.001 1.74 (1.21-2.50), P = 0.003 
NT-proBNP 
   
6 months 1.58 (0.91-2.75), P = 0.107 2.35 (1.25-4.40), P = 0.008 1.63 (1.01-2.63), P = 0.045 
1 year 1.45 (0.91-2.30), P = 0.118 2.49 (1.42-4.37), P = 0.001 1.68 (1.10-2.56), P = 0.016 
2 years 1.45 (0.94-2.23), P = 0.092 2.50 (1.49-4.20), P = 0.001 1.64 (1.11-2.43), P = 0.014 
BNP, B-type natriuretic peptide; HF, heart failure; MACE, major adverse cardiac event; MI, 
myocardial infarction; NT-proBNP, N-terminal pro B-type natriuretic peptide 
 
 
